Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057970 | PMC |
| http://dx.doi.org/10.1007/s12094-020-02534-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective.
Clin Transl Oncol
January 2025
Medical Oncology Department, Hospital del Mar, Parc de Salut Mar, Spanish Group for Breast Cancer Research (GEICAM), Barcelona, Spain.
Therapeutic decision-making for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer highlights the importance of a comprehensive geriatric assessment (CGA). This assessment considers the functional status, comorbidities, and relevant conditions of the patient, and allows for an estimation of life expectancy, but it does not facilitate individualized treatment plans. There are also other challenges to consider related to the cardiac toxicity of the treatments and the under-representation of older patients in clinical trials.
View Article and Find Full Text PDFCancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding.
Haematologica
December 2024
Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM).
Article Synopsis
- * In a study involving 2,823 cancer patients, both sexes experienced pulmonary embolism as the most common type of venous thromboembolic event, with differing rates of rethrombosis: 10.0% for men and 15.0% for women after a median follow-up of 6.9 months.
- * Men experienced a higher incidence of major bleeding compared to women, making sex an important consideration in determining the length of anticoagulant therapy for cancer patients, especially with specific risk factors involved.
Sentinels of neuroinflammation: the crucial role of myeloid cells in the pathogenesis of gliomas and neurodegenerative diseases.
J Neuroinflammation
November 2024
Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain.
Article Synopsis
- The review discusses the significant role of myeloid cells in the inflammatory processes of central nervous system (CNS) diseases, specifically gliomas (brain tumors) and neurodegenerative disorders like Alzheimer's and Parkinson's disease.
- It highlights the similarities in chronic inflammation and immune dysfunction that these diseases share, despite their different symptoms and treatment challenges.
- Advances in research, particularly single-cell technologies, are explored to uncover the diverse functions of myeloid cells and suggest novel therapeutic targets for improving treatment outcomes in these conditions.
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
Clin Cancer Res
January 2025
Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Purpose: The MammaPrint (MP) prognostic assay categorizes breast cancers into high- and low-risk subgroups, and the high-risk group can be further subdivided into high-1 (MP-H1), and very high-risk high-2 (MP-H2). The aim of this analysis was to assess clinical and molecular differences between the hormone receptor-positive (HR+)/HER2-negative MP-H1, -H2, and triple-negative (TN) MP-H1 and -H2 cancers.
Experimental Design: Pretreatment gene expression data from 742 HER2-negative breast cancers enrolled in the I-SPY2 neoadjuvant trial were used.
IORT-photon boost plus hypofractionated whole breast irradiation in patients with breast cancer after primary systemic treatment: feasibility, safety and clinical results.
Clin Transl Oncol
October 2024
Centro Oncologico Integral Canario, Hospital Universitario San Roque, Universidad Fernando Pessoa Canarias, Insituto Canario de Investigación del Cáncer, Las Palmas, Spain.
Aim: To assess for the first time the safety and feasibility of combining photon-intraoperative radiotherapy (ph-IORT) with hypofractionated whole breast irradiation (h-WBI) in patients referred to primary systemic therapy (PST).
Methods: From March 2019 to December 2020, patients referred for breast conservative surgery (BCS) after PST in our institution were prospectively included in the present trial. PST was prescribed to all patients according the ESMO-SEOM guidelines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!